USA flag logo/image

An Official Website of the United States Government

IGF::OT::IGF OTHER FUNCTIONS TAS:: 750849 REFORMULATION OF CANCER THERAPEUTICS…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
N43CO120092
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
Small Business Information
LIPOMEDICS LTD
LIPOMEDICS, LIMITED COMPANY 4340 WEDGWORTH CT FORT WORTH, TX 76133-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: IGF::OT::IGF OTHER FUNCTIONS TAS:: 750849 REFORMULATION OF CANCER THERAPEUTICS USING NANOTECHNOLOGY
Agency: HHS
Contract: N43CO120092
Award Amount: $191,326.00
 

Abstract:

The aim of this project is to reformulate a highly lipophilic anti-cancer agent, valrubicin (AD-32) that has only been approved for vesicular treatment of bladder cancer due to its poor dose limiting toxicities due to poor water solubility. LipoMedics willreformulate valrubicin (AD-32) utilizing a robust, novel biocompatible drug delivery system, composed of reconstituted high density lipoprotein (rHDL) nanoparticles that are particularly effective in improving solubility and safety of poorly soluble drugs. The additional advantage of formulating drugs with rHDL is the selective targeting toward malignant tumors via the SR-B1 receptor. LipoMedics intends to conduct proof of concept studies to evaluate therapeutic efficacy of the rHDL/AD-32 drug formulationversus that of the free drug. These studies will include assessment of cytotoxicity versus cancer cells, stability of the rHDL/AD-32 formulation and tumor suppression studies in mice. The major goal of these studies is to demonstrate enhancement in therapeutic efficacy of AD-32 via encapsulation in rHDL nanoparticles. Based on previous studies, it is anticipated that AD-32, as an initial model, and subsequently a wide range of similarly lipophilic drugs, can be reformulated to produce clinically effective anti-cancer drugs as well as profitable ventures for biotech entrepreneurs.

Principal Investigator:

Walter Mcconathy
432-212-2416
MC123@ATT.NET

Business Contact:

Walter Mcconathy
432-212-2416
MC123@ATT.NET
Small Business Information at Submission:

LIPOMEDICS LTD
LIPOMEDICS, LIMITED COMPANY 4340 WEDGWORTH CT FORT WORTH, TX 76133-

EIN/Tax ID: 999999999
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No